Free Trial
→ 📉 Volatility Surges Amid Political Turmoil—Here's How Traders Are Responding (From Darwin) (Ad) Buy COGT Stock  Free COGT Stock Alerts

Cogent Biosciences (COGT) Financials

Cogent Biosciences logo
$7.23 -0.01 (-0.14%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$7.23 0.00 (0.00%)
As of 06/20/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Cogent Biosciences

Annual Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -26 -35 -32 -179 -72 -140 -192 -256
Consolidated Net Income / (Loss)		 -25 -35 -32 -75 -72 -140 -192 -256
Net Income / (Loss) Continuing Operations		 -25 -35 -32 -118 -73 -142 -194 -256
Total Pre-Tax Income 		-25 -35 -32 -118 -73 -142 -194 -256
Total Operating Income		 -26 -36 -32 -82 -76 -148 -208 -276
Total Gross Profit		 8.36 9.73 22 7.87 0.00 0.00 0.00 0.00
Total Revenue		 8.36 9.73 22 7.87 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 35 46 55 133 76 148 208 276
Selling, General & Admin Expense		 4.68 7.45 11 17 20 26 34 43
Research & Development Expense		 30 38 44 26 56 122 174 233
Total Other Income / (Expense), net		 0.66 1.47 0.35 7.39 3.28 7.60 16 20
Interest & Investment Income		 0.39 1.15 0.27 0.14 0.47 3.99 13 18
Other Income / (Expense), net		 0.27 0.32 0.08 7.25 2.47 2.25 0.94 1.99
Basic Earnings per Share		 ($2.51) ($1.39) ($4.18) ($16.17) ($1.87) ($433.56) ($488.17) ($2,426.26)
Weighted Average Basic Shares Outstanding		 10.19M 24.90M 7.62M 11.08M 38.73M 58.83M 79.74M 103.94M
Diluted Earnings per Share		 ($2.51) ($1.39) ($4.18) ($16.17) ($1.87) ($433.56) ($488.17) ($2,426.26)
Weighted Average Diluted Shares Outstanding		 10.19M 24.90M 7.62M 11.08M 38.73M 58.83M 79.74M 103.94M
Weighted Average Basic & Diluted Shares Outstanding		 10.19M 24.90M 7.62M 11.08M 38.73M 69.95M 103.91M 113.85M

Quarterly Income Statements for Cogent Biosciences

This table shows Cogent Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68 -72
Consolidated Net Income / (Loss)		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68 -72
Net Income / (Loss) Continuing Operations		 -35 -41 -39 -44 -55 -56 -58 -59 -71 -68 -72
Total Pre-Tax Income 		-35 -41 -39 -44 -55 -56 -58 -59 -71 -68 -72
Total Operating Income		 -37 -44 -43 -47 -60 -58 -62 -64 -75 -74 -75
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 37 44 43 47 60 58 62 64 75 74 75
Selling, General & Admin Expense		 6.89 7.00 7.20 8.21 9.45 9.51 9.70 10 12 12 12
Research & Development Expense		 30 37 36 39 50 49 53 54 64 62 63
Total Other Income / (Expense), net		 1.76 4.13 4.65 3.01 4.20 3.86 4.06 5.44 4.78 5.81 2.95
Interest & Investment Income		 1.50 2.11 2.27 2.74 4.20 3.87 4.06 5.39 4.78 3.86 2.95
Other Income / (Expense), net		 0.26 0.66 2.38 0.27 0.00 -1.71 -0.00 0.04 0.00 1.95 -0.01
Basic Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($607.97) ($0.59) ($0.64) ($2,424.41) ($656.64)
Weighted Average Basic Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.89M 99.24M 110.17M 103.94M 113.38M
Diluted Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($607.97) ($0.59) ($0.64) ($2,424.41) ($656.64)
Weighted Average Diluted Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.89M 99.24M 110.17M 103.94M 113.38M
Weighted Average Basic & Diluted Shares Outstanding		 69.89M 69.95M 70.95M 85.47M 86.12M 103.91M 95.61M 109.45M 110.46M 113.85M 113.86M

Annual Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -13 27 -18 205 -23 -80 -88 45
Net Cash From Operating Activities		 -26 -32 -42 -36 -59 -119 -154 -208
Net Cash From Continuing Operating Activities		 -26 -32 -42 -36 -59 -119 -153 -208
Net Income / (Loss) Continuing Operations		 -25 -35 -32 -75 -72 -140 -192 -256
Consolidated Net Income / (Loss)		 -25 -35 -32 -75 -72 -140 -192 -256
Depreciation Expense		 1.17 1.32 1.29 0.72 0.15 0.84 2.27 2.45
Amortization Expense		 0.02 -0.25 -0.05 - 1.84 3.40 -5.17 -5.72
Non-Cash Adjustments To Reconcile Net Income		 1.35 3.12 3.06 43 12 18 30 40
Changes in Operating Assets and Liabilities, net		 -2.88 -2.15 -14 -4.96 -0.17 -0.61 12 12
Net Cash From Investing Activities		 14 -11 23 8.42 -1.72 -125 -98 38
Net Cash From Continuing Investing Activities		 14 -11 23 8.42 -1.72 -125 -98 38
Purchase of Property, Plant & Equipment		 -0.91 -0.55 - 0.00 -1.72 -6.86 -2.80 -0.57
Purchase of Investments		 -6.50 -48 - - 0.00 -178 -349 -256
Sale and/or Maturity of Investments		 21 38 23 - 0.00 60 254 294
Net Cash From Financing Activities		 -0.73 70 0.11 232 38 164 164 214
Net Cash From Continuing Financing Activities		 -0.73 70 0.11 232 38 164 164 214
Issuance of Common Equity		 0.06 72 0.00 133 38 162 163 214
Other Financing Activities, net		 - - 0.11 0.51 -0.06 1.26 0.97 0.20

Quarterly Cash Flow Statements for Cogent Biosciences

This table details how cash moves in and out of Cogent Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -185 -0.68 21 52 -128 -34 163 -128 8.83 1.12 28
Net Cash From Operating Activities		 -34 -29 -40 -32 -38 -44 -53 -43 -52 -61 -67
Net Cash From Continuing Operating Activities		 -34 -29 -40 -32 -38 -44 -53 -43 -52 -61 -67
Net Income / (Loss) Continuing Operations		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68 -72
Consolidated Net Income / (Loss)		 -35 -40 -39 -44 -55 -54 -58 -59 -71 -68 -72
Depreciation Expense		 0.26 0.42 0.53 0.56 0.58 0.60 0.60 0.61 0.62 0.63 0.64
Amortization Expense		 3.00 -0.67 -0.85 -0.08 1.18 -5.42 -0.93 3.06 -5.72 -2.12 -0.46
Non-Cash Adjustments To Reconcile Net Income		 4.23 5.04 5.85 7.16 8.76 8.06 9.39 10 10 9.98 10
Changes in Operating Assets and Liabilities, net		 -6.86 5.42 -6.46 4.37 6.89 7.44 -3.24 2.58 13 -1.13 -4.72
Net Cash From Investing Activities		 -152 28 60 -78 -91 10 1.04 -85 60 62 69
Net Cash From Continuing Investing Activities		 -152 28 60 -78 -91 10 1.04 -85 60 62 69
Purchase of Property, Plant & Equipment		 -3.31 -1.97 -1.10 -1.26 -0.12 -0.32 -0.07 -0.15 -0.28 -0.08 -0.55
Purchase of Investments		 -148 -30 -59 -126 -112 -51 -73 -150 -19 -13 0.00
Sale and/or Maturity of Investments		 - 60 120 50 22 62 74 66 80 74 70
Net Cash From Financing Activities		 0.99 0.32 0.45 162 1.00 - 214 -0.26 0.62 0.03 25
Net Cash From Continuing Financing Activities		 0.99 0.32 0.45 162 1.00 - 214 -0.26 0.62 0.03 25
Issuance of Common Equity		 0.05 - 0.31 162 0.27 - 214 -0.37 0.56 -0.00 25
Other Financing Activities, net		 0.94 0.32 0.13 0.10 0.73 - 0.00 0.11 0.06 0.03 0.14

Annual Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 49 86 49 251 232 301 313 328
Total Current Assets		 42 81 41 245 223 265 271 296
Cash & Equivalents		 28 56 37 242 220 140 53 98
Short-Term Investments		 13 23 - - 0.00 119 212 189
Prepaid Expenses		 0.51 0.74 1.17 2.72 2.95 4.44 5.06 9.40
Plant, Property, & Equipment, net		 4.11 3.25 1.87 0.13 1.71 7.78 8.34 6.47
Total Noncurrent Assets		 2.63 1.67 6.97 5.87 7.75 28 34 25
Long-Term Investments		 - - - - - 0.00 7.46 0.00
Other Noncurrent Operating Assets		 2.63 1.67 6.97 5.87 7.75 28 27 25
Total Liabilities & Shareholders' Equity		 49 86 49 251 232 301 313 328
Total Liabilities		 21 26 18 16 18 45 56 72
Total Current Liabilities		 11 25 13 13 17 27 38 56
Accounts Payable		 1.35 1.52 3.18 0.73 3.48 5.84 11 12
Accrued Expenses		 2.95 5.48 7.13 4.78 8.21 18 26 42
Other Current Liabilities		 - - 1.62 7.58 5.38 3.12 1.39 1.57
Total Noncurrent Liabilities		 9.62 0.75 4.41 3.16 0.83 18 17 16
Other Noncurrent Operating Liabilities		 - - 4.41 3.16 0.83 18 17 16
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 60 32 235 214 256 258 256
Total Preferred & Common Equity		 -49 60 32 235 214 256 258 256
Preferred Stock		 0.00 0.00 0.00 111 85 66 60 111
Total Common Equity		 -49 60 32 124 129 190 198 146
Common Stock		 2.51 152 156 322 400 601 801 1,005
Retained Earnings		 -51 -92 -124 -199 -271 -411 -604 -859
Accumulated Other Comprehensive Income / (Loss)		 -0.02 -0.01 - - 0.00 -0.10 0.25 0.45

Quarterly Balance Sheets for Cogent Biosciences

This table presents Cogent Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 366 332 263 392 355 476 430 384 284
Total Current Assets		 331 296 226 335 286 442 370 342 253
Cash & Equivalents		 326 141 161 214 87 216 88 97 126
Short-Term Investments		 - 149 60 115 192 220 275 238 120
Prepaid Expenses		 3.86 6.07 4.75 5.12 6.91 6.16 6.76 6.01 7.22
Plant, Property, & Equipment, net		 3.59 6.54 9.03 9.10 8.64 7.82 7.36 7.02 6.45
Total Noncurrent Assets		 32 29 28 49 61 26 53 35 24
Long-Term Investments		 - - - 22 34 0.00 27 10 0.00
Other Noncurrent Operating Assets		 32 29 28 27 27 26 26 25 24
Total Liabilities & Shareholders' Equity		 366 332 263 392 355 476 430 384 284
Total Liabilities		 47 42 40 44 53 54 57 69 65
Total Current Liabilities		 28 24 21 26 35 37 40 53 49
Accounts Payable		 3.49 4.09 4.17 7.16 9.87 16 8.98 15 14
Accrued Expenses		 12 14 16 17 24 20 30 36 34
Other Current Liabilities		 12 5.07 0.95 1.18 1.34 1.43 1.48 1.52 1.61
Total Noncurrent Liabilities		 19 18 19 18 18 17 17 16 15
Other Noncurrent Operating Liabilities		 19 18 19 18 18 17 17 16 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 319 290 224 348 303 422 373 315 219
Total Preferred & Common Equity		 319 290 224 348 303 422 373 315 219
Preferred Stock		 71 66 62 62 60 222 114 111 108
Total Common Equity		 248 224 161 286 243 200 259 204 111
Common Stock		 585 596 611 780 792 862 980 995 1,042
Retained Earnings		 -337 -372 -450 -494 -549 -662 -721 -792 -931
Accumulated Other Comprehensive Income / (Loss)		 - -0.16 0.02 -0.10 -0.17 -0.04 -0.19 0.90 0.16

Annual Metrics And Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 16.44% 131.14% -65.02% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -40.18% 10.84% -140.54% 4.23% -98.83% -48.63% -31.95%
EBIT Growth		 0.00% -37.90% 10.05% -133.50% 2.49% -99.21% -42.31% -32.22%
NOPAT Growth		 0.00% -37.68% 10.63% -155.45% 8.09% -95.68% -40.78% -32.58%
Net Income Growth		 0.00% -35.46% 7.82% -135.00% 3.39% -94.04% -37.20% -32.98%
EPS Growth		 0.00% 44.62% 7.82% -286.84% 88.44% -23,085.03% -12.60% -397.01%
Operating Cash Flow Growth		 0.00% -25.76% -27.78% 13.64% -63.91% -101.89% -29.49% -35.26%
Free Cash Flow Firm Growth		 0.00% 0.00% -79.94% -58.08% 1.38% -89.75% -29.68% -31.54%
Invested Capital Growth		 0.00% -44.21% 69.16% -32.87% 26.89% 12.80% -220.43% -100.36%
Revenue Q/Q Growth		 0.00% 20.89% 104.24% -66.01% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -7.03% 26.93% -10.00% -20.43% -15.07% -11.36% -3.17%
EBIT Q/Q Growth		 0.00% -6.65% 26.07% -9.41% -23.60% -13.86% -8.85% -4.52%
NOPAT Q/Q Growth		 0.00% -6.27% 25.89% -19.99% -23.11% -13.96% -7.48% -5.95%
Net Income Q/Q Growth		 0.00% -5.87% 25.51% -22.29% -23.12% -11.71% -8.30% -5.60%
EPS Q/Q Growth		 0.00% -27.52% 25.51% -121.81% 51.17% -23,986.67% -23,597.57% -97,340.16%
Operating Cash Flow Q/Q Growth		 0.00% -8.35% 1.37% -2.64% -24.10% -7.85% -10.55% -8.63%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -7.63% -7.39% -8.37% -8.47% -7.22% -10.15%
Invested Capital Q/Q Growth		 0.00% 6.27% 67.19% 43.70% 2.65% -1,078.38% -54.65% 0.32%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -295.33% -355.56% -137.16% -943.11% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -312.82% -369.89% -143.02% -1,044.33% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -309.55% -366.60% -142.67% -952.26% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -304.93% -354.76% -141.49% -950.43% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 63.41% 99.53% 99.04% 99.12% 100.00%
Interest Burden Percent		 98.51% 96.77% 99.17% 157.39% 99.36% 97.26% 93.69% 93.40%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -90.06% -78.00% -69.21% -56.16% -32.20% -59.69% -74.94% -99.54%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -52.69% -52.85% -47.43% -49.91% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -51.90% -51.14% -47.04% -49.82% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 155.42% -10.03% -69.21% -32.79% -18.12% -40.48% -56.57% -66.50%
Return on Equity Simple (ROE_SIMPLE)		 52.19% -57.33% -100.22% -31.88% -33.74% -54.84% -74.63% -99.83%
Net Operating Profit after Tax (NOPAT)		 -18 -25 -23 -58 -53 -103 -146 -193
NOPAT Margin		 -218.98% -258.92% -100.11% -731.03% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -17.51% -15.60% -16.05% -12.35% -8.40% -15.31% -17.51% -22.38%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -40.47% -56.51% -75.37%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 55.98% 76.58% 48.75% 221.34% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 356.84% 393.31% 194.27% 327.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 412.82% 469.89% 243.02% 1,692.67% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -36 -32 -75 -73 -146 -207 -274
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -35 -31 -74 -71 -141 -210 -277
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.19 0.70 0.26 2.66 4.25 2.56 5.91
Price to Tangible Book Value (P/TBV)		 0.00 2.19 0.70 0.26 2.66 4.25 2.56 5.91
Price to Revenue (P/Rev)		 8.28 13.56 0.98 4.05 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 12.60 5.48 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.45 -1.35 -1.26 -1.05 -1.03 -1.02 -1.04 -1.09
Leverage Ratio		 1.74 1.53 1.47 1.13 1.08 1.13 1.20 1.25
Compound Leverage Factor		 1.71 1.48 1.46 1.77 1.07 1.10 1.12 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 47.25% 39.87% 25.74% 23.29% 43.15%
Noncontrolling Interests to Total Capital		 272.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -172.57% 100.00% 100.00% 52.75% 60.13% 74.26% 76.71% 56.85%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.27 1.11 -3.78 0.22 9.85 8.19 1.47 1.67
Noncontrolling Interest Sharing Ratio		 272.57% 87.14% 0.00% 41.62% 43.73% 32.18% 24.51% 33.19%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 3.79 3.25 3.06 18.70 13.04 9.87 7.09 5.32
Quick Ratio		 3.73 3.22 2.98 18.50 12.86 9.66 6.96 5.15
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -20 -35 -56 -55 -104 -135 -178
Operating Cash Flow to CapEx		 -2,832.79% -5,917.85% 0.00% 0.00% -3,418.44% -1,728.66% -5,494.42% -36,263.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.17 0.14 0.33 0.05 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 10.07 7.79 12.27 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.04 2.65 8.80 7.87 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 36.24 46.83 29.75 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 36.24 46.83 29.75 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -13 -18 -5.66 -7.52 -5.50 -4.80 -15 -31
Invested Capital Turnover		 -0.66 -0.63 -1.87 -1.19 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -5.63 13 -1.86 2.02 0.70 -11 -15
Enterprise Value (EV)		 105 53 -15 -99 208 613 293 685
Market Capitalization		 69 132 22 32 342 808 506 862
Book Value per Share		 ($4.79) $2.01 $1.04 $10.91 $3.23 $2.72 $2.30 $1.32
Tangible Book Value per Share		 ($4.79) $2.01 $1.04 $10.91 $3.23 $2.72 $2.30 $1.32
Total Capital		 28 60 32 235 214 256 258 256
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -41 -79 -37 -242 -220 -261 -273 -287
Capital Expenditures (CapEx)		 0.91 0.55 -0.24 -0.32 1.72 6.86 2.80 0.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.85 -23 -10 -10 -14 -22 -33 -46
Debt-free Net Working Capital (DFNWC)		 31 56 27 232 206 238 233 241
Net Working Capital (NWC)		 31 56 27 232 206 238 233 241
Net Nonoperating Expense (NNE)		 7.19 9.33 9.31 17 19 37 47 63
Net Nonoperating Obligations (NNO)		 -41 -79 -37 -242 -220 -261 -273 -287
Total Depreciation and Amortization (D&A)		 1.19 1.08 1.24 0.72 1.99 4.24 -2.90 -3.27
Debt-free, Cash-free Net Working Capital to Revenue		 -117.79% -231.53% -44.81% -131.77% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 373.07% 575.89% 121.53% 2,945.22% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 373.07% 575.89% 121.53% 2,945.22% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 ($10.04) ($5.56) ($4.16) ($16.17) ($1.87) ($2.39) ($2.42) ($2,426.26)
Adjusted Weighted Average Basic Shares Outstanding		 2.55M 7.52M 7.65M 37.19M 45.81M 58.74M 79.66M 103.94M
Adjusted Diluted Earnings per Share		 ($10.04) ($5.56) ($4.16) ($16.17) ($1.87) ($2.39) ($2.42) ($2,426.26)
Adjusted Weighted Average Diluted Shares Outstanding		 2.55M 7.52M 7.65M 37.19M 45.81M 58.74M 79.66M 103.94M
Adjusted Basic & Diluted Earnings per Share		 ($10.04) ($5.56) ($4.16) ($16.17) ($1.87) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.55M 6.22M 7.62M 11.08M 38.73M 69.95M 103.91M 113.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -25 -23 -58 -53 -103 -146 -193
Normalized NOPAT Margin		 -218.98% -258.92% -100.11% -731.03% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -304.93% -354.76% -141.49% -1,498.77% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.10% -5.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cogent Biosciences

This table displays calculated financial ratios and metrics derived from Cogent Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -78.26% -74.62% -36.43% -34.20% -73.59% -49.45% -52.36% -30.96% -39.26% -13.16% -19.16%
EBIT Growth		 -90.44% -69.89% -32.90% -33.01% -62.96% -39.10% -52.75% -37.44% -26.57% -19.77% -20.08%
NOPAT Growth		 -85.79% -70.61% -37.62% -31.32% -61.81% -33.11% -44.33% -36.75% -26.58% -26.63% -20.08%
Net Income Growth		 -83.72% -59.03% -25.96% -26.19% -57.95% -37.22% -51.21% -33.75% -27.54% -24.95% -23.37%
EPS Growth		 -4.17% -4.69% 19.12% 16.90% -28.00% -72,495.52% -12.73% 0.00% 0.00% -398.45% -8.01%
Operating Cash Flow Growth		 -144.10% -41.54% -39.47% -21.21% -10.25% -49.86% -32.93% -33.17% -36.90% -37.46% -26.62%
Free Cash Flow Firm Growth		 -43.70% -56.85% -55.78% -65.05% -3.73% 3.63% 20.46% 18.56% 1.05% -19.89% -38.82%
Invested Capital Growth		 92.80% 12.80% 164.20% 66.59% -2,341.52% -220.43% -755.87% -571.81% -210.85% -100.36% -98.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 3.54% -30.10% 4.98% -12.54% -24.77% -12.01% 3.13% 3.27% -32.69% 8.98% -2.01%
EBIT Q/Q Growth		 -3.87% -17.85% 5.18% -14.59% -27.26% -0.60% -4.12% -3.11% -17.20% 4.81% -4.39%
NOPAT Q/Q Growth		 -2.69% -18.80% 1.16% -8.90% -26.54% 2.27% -7.17% -3.18% -17.13% 2.23% -1.63%
Net Income Q/Q Growth		 -0.39% -12.99% 2.60% -14.23% -25.65% 1.84% -7.33% -1.03% -19.82% 3.83% -5.98%
EPS Q/Q Growth		 29.58% -34.00% 17.91% -7.27% -8.47% -75,898.44% 3.13% 4.84% -8.47% -378,714.06% 72.92%
Operating Cash Flow Q/Q Growth		 -30.18% 14.61% -34.38% 18.86% -18.42% -16.06% -19.19% 18.71% -21.74% -16.53% -9.80%
Free Cash Flow Firm Q/Q Growth		 -35.05% -0.99% -13.31% -6.80% 15.12% 6.18% 6.48% -9.35% -3.13% -13.67% -8.30%
Invested Capital Q/Q Growth		 94.52% -1,078.38% 142.62% -221.48% -300.20% -54.65% 12.77% -24.43% -85.17% 0.32% 13.40%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 96.68% 100.00% 100.00% 100.00% 96.97% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.90% 95.10% 94.45% 94.15% 92.95% 93.54% 93.50% 91.62% 93.66% 94.62% 96.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -51.54% -59.69% -72.04% -47.12% -59.94% -74.94% -65.70% -62.92% -78.47% -99.54% -84.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -5,723.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -44.57% -40.48% -47.40% -37.69% -47.21% -56.57% -36.76% -47.54% -56.79% -66.50% -40.76%
Return on Equity Simple (ROE_SIMPLE)		 -43.30% 0.00% -66.29% -45.16% -58.65% 0.00% -50.24% -60.83% -77.00% 0.00% -123.06%
Net Operating Profit after Tax (NOPAT)		 -26 -31 -30 -33 -42 -41 -44 -45 -53 -52 -52
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.77% -3.75% -4.03% -3.28% -4.53% -5.10% -4.46% -3.75% -5.42% -5.82% -5.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.97% - - - -15.81% - - - -20.14% -23.95%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -37 -43 -41 -47 -60 -60 -62 -64 -75 -72 -75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -33 -43 -41 -46 -58 -65 -63 -61 -81 -73 -75
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.38 4.25 4.68 2.94 3.43 2.56 2.89 3.11 5.79 5.91 6.15
Price to Tangible Book Value (P/TBV)		 4.38 4.25 4.68 2.94 3.43 2.56 2.89 3.11 5.79 5.91 6.15
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 291.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.02 -1.00 -1.01 -1.02 -1.04 -1.02 -1.03 -1.07 -1.09 -1.06
Leverage Ratio		 1.12 1.13 1.14 1.14 1.16 1.20 1.14 1.14 1.20 1.25 1.18
Compound Leverage Factor		 1.08 1.08 1.08 1.07 1.08 1.12 1.07 1.04 1.12 1.18 1.14
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 22.70% 25.74% 27.87% 17.88% 19.82% 23.29% 52.60% 30.58% 35.15% 43.15% 49.39%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 77.30% 74.26% 72.13% 82.12% 80.18% 76.71% 47.40% 69.42% 64.85% 56.85% 50.61%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 13.20 9.32 9.46 10.26 7.65 3.02 5.10 6.61 7.59 3.71 1.71
Noncontrolling Interest Sharing Ratio		 13.51% 32.18% 34.20% 20.02% 21.23% 24.51% 44.04% 24.45% 27.63% 33.19% 51.51%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.59 9.87 10.71 12.99 8.24 7.09 12.05 9.25 6.44 5.32 5.13
Quick Ratio		 12.28 9.66 10.43 12.79 8.04 6.96 11.88 9.08 6.32 5.15 4.98
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -31 -31 -35 -38 -32 -30 -28 -31 -32 -36 -39
Operating Cash Flow to CapEx		 -1,040.17% -1,495.07% -3,582.68% -2,550.99% -31,380.99% -13,990.48% -75,041.43% -28,852.03% -18,565.71% -80,769.33% -12,159.23%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.41 -4.80 2.04 -2.48 -9.94 -15 -13 -17 -31 -31 -27
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.24 0.70 5.23 4.95 -9.53 -11 -15 -14 -21 -15 -13
Enterprise Value (EV)		 757 613 596 551 580 293 365 530 947 685 544
Market Capitalization		 981 808 755 840 833 506 579 806 1,182 862 682
Book Value per Share		 $3.41 $2.72 $2.31 $4.03 $2.84 $2.30 $2.11 $2.71 $1.86 $1.32 $0.97
Tangible Book Value per Share		 $3.41 $2.72 $2.31 $4.03 $2.84 $2.30 $2.11 $2.71 $1.86 $1.32 $0.97
Total Capital		 290 256 224 348 303 258 422 373 315 256 219
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -290 -261 -222 -351 -313 -273 -436 -390 -346 -287 -246
Capital Expenditures (CapEx)		 3.31 1.97 1.10 1.26 0.12 0.32 0.07 0.15 0.28 0.08 0.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -22 -16 -21 -28 -33 -31 -33 -47 -46 -42
Debt-free Net Working Capital (DFNWC)		 273 238 205 309 251 233 405 330 288 241 204
Net Working Capital (NWC)		 273 238 205 309 251 233 405 330 288 241 204
Net Nonoperating Expense (NNE)		 9.29 9.00 8.32 11 14 14 15 14 18 16 20
Net Nonoperating Obligations (NNO)		 -290 -261 -222 -351 -313 -273 -436 -390 -346 -287 -246
Total Depreciation and Amortization (D&A)		 3.26 -0.25 -0.32 0.48 1.76 -4.83 -0.33 3.66 -5.10 -1.50 0.18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($0.62) ($0.59) ($0.64) ($2,424.41) ($656.64)
Adjusted Weighted Average Basic Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.80M 99.24M 110.17M 103.94M 113.38M
Adjusted Diluted Earnings per Share		 ($0.50) ($0.67) ($0.55) ($0.59) ($0.64) ($486.39) ($0.62) ($0.59) ($0.64) ($2,424.41) ($656.64)
Adjusted Weighted Average Diluted Shares Outstanding		 69.58M 58.83M 70.73M 74.75M 86.17M 79.74M 94.80M 99.24M 110.17M 103.94M 113.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.67) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 69.89M 69.95M 70.95M 85.47M 86.12M 103.91M 95.61M 109.45M 110.46M 113.85M 113.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -31 -30 -33 -42 -41 -44 -45 -53 -52 -52
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Cogent Biosciences (NASDAQ:COGT) reported its Q1 2025 results with a strong liquidity position despite continued development‐stage losses. Key financial and operational highlights include:

  • Cash & equivalents of $126.0 million as of March 31, 2025, providing runway for ongoing R&D activities.
  • Short-term investments of $119.7 million and net cash inflow of $69.4 million from maturity of investments in Q1 2025.
  • No debt on the balance sheet; net debt of –$246.0 million supports development until potential commercialization.
  • Strong liquidity metrics: current ratio of 5.13x and quick ratio of 4.98x at quarter end.
  • Market capitalization of $682 million versus enterprise value of $544 million reflects investor confidence in the pipeline.
  • Book value per share at $0.97, with a P/B multiple of 6.15x, signaling a premium assigned to future prospects.
  • Q1 2025 net loss widened to $72.0 million, up from $68.0 million in Q1 2024, driven by increased operating expenses.
  • Operating cash flow was negative $66.5 million and free cash flow to firm was –$39.2 million, underscoring the high burn rate.
  • R&D expense rose to $63.0 million and SG&A to $11.9 million in Q1 2025, reflecting intensified development spending.
  • No revenue reported since inception; commercialization remains contingent on clinical and regulatory milestones.
06/21/25 12:48 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Cogent Biosciences' Financials

When does Cogent Biosciences' fiscal year end?

According to the most recent income statement we have on file, Cogent Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cogent Biosciences' net income changed over the last 7 years?

Cogent Biosciences' net income appears to be on an upward trend, with a most recent value of -$255.86 million in 2024, rising from -$25.49 million in 2017. The previous period was -$192.41 million in 2023. See Cogent Biosciences' forecast for analyst expectations on what’s next for the company.

What is Cogent Biosciences' operating income?
Cogent Biosciences' total operating income in 2024 was -$275.94 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $275.94 million
How has Cogent Biosciences' revenue changed over the last 7 years?

Over the last 7 years, Cogent Biosciences' total revenue changed from $8.36 million in 2017 to $0.00 in 2024, a change of -100.0%.

How much debt does Cogent Biosciences have?

Cogent Biosciences' total liabilities were at $71.61 million at the end of 2024, a 28.7% increase from 2023, and a 244.1% increase since 2017.

How much cash does Cogent Biosciences have?

In the past 7 years, Cogent Biosciences' cash and equivalents has ranged from $28.27 million in 2017 to $242.19 million in 2020, and is currently $98.17 million as of their latest financial filing in 2024.

How has Cogent Biosciences' book value per share changed over the last 7 years?

Over the last 7 years, Cogent Biosciences' book value per share changed from -4.79 in 2017 to 1.32 in 2024, a change of -127.5%.


Related Companies

This page (NASDAQ:COGT) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...
American Alternative | Sponsored
The IRS Loophole That Lets You Own Gold Tax-Free
What if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...
Advantage Gold | Sponsored